Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
Kamada (NASDAQ: KMDA) announced the opening of a new plasma collection center in San Antonio, Texas, marking its third such facility. The 11,100 square foot center, operated by Kamada Plasma, will feature nearly 50 donor beds with an estimated annual collection capacity of 50,000 liters.
The facility will collect both normal source plasma and specialty plasma (Anti-Rabies and Anti-D), supporting the company's increasing demand for hyper-immune plasma while aiming to reduce raw material costs. At full capacity, the center is projected to generate $8-10 million in annual revenue from normal source plasma sales to third parties.
Kamada plans to submit approval applications to the U.S. FDA and European Medicines Agency in the second half of 2025, with anticipated approval decisions expected within 9-12 months of submission.
Kamada (NASDAQ: KMDA) ha annunciato l'apertura di un nuovo centro di raccolta plasma a San Antonio, Texas, segnando la sua terza struttura di questo tipo. Il centro, che occupa 11.100 piedi quadrati e gestito da Kamada Plasma, avrà quasi 50 letti per donatori con una capacità di raccolta annuale stimata di 50.000 litri.
La struttura raccoglierà sia plasma normale che plasma speciale (Anti-Rabbia e Anti-D), supportando la crescente domanda dell'azienda per plasma iperimmune, con l'obiettivo di ridurre i costi delle materie prime. A piena capacità, il centro prevede di generare $8-10 milioni di entrate annuali dalle vendite di plasma normale a terzi.
Kamada prevede di presentare domande di approvazione alla FDA degli Stati Uniti e all'
Kamada (NASDAQ: KMDA) anunció la apertura de un nuevo centro de recolección de plasma en San Antonio, Texas, marcando su tercera instalación de este tipo. El centro, que ocupa 11,100 pies cuadrados y es operado por Kamada Plasma, contará con casi 50 camas para donantes y una capacidad de recolección anual estimada de 50,000 litros.
La instalación recogerá tanto plasma normal como plasma especial (Anti-Rábico y Anti-D), apoyando la creciente demanda de la empresa por plasma hiperinmune, mientras busca reducir los costos de las materias primas. A plena capacidad, se prevé que el centro genere $8-10 millones en ingresos anuales por ventas de plasma normal a terceros.
Kamada planea presentar solicitudes de aprobación a la FDA de EE. UU. y a la Agencia Europea de Medicamentos en la segunda mitad de 2025, con decisiones de aprobación anticipadas esperadas dentro de 9-12 meses después de la presentación.
카마다 (NASDAQ: KMDA)는 텍사스주 샌안토니오에 새로운 혈장 수집 센터를 개소했다고 발표하며, 이는 세 번째 시설입니다. 11,100 평방 피트 규모의 이 센터는 카마다 플라즈마가 운영하며, 약 50개의 기증자 침대를 갖추고 연간 50,000 리터의 수집 용량을 예상하고 있습니다.
이 시설은 일반 혈장과 특수 혈장(항광견병 및 항-D)을 모두 수집하여, 회사의 고면역 혈장에 대한 증가하는 수요를 지원하고 원자재 비용을 줄이는 것을 목표로 합니다. 최대 용량에 도달하면, 이 센터는 제3자에게 판매되는 일반 혈장에서 $8-10 백만의 연간 수익을 창출할 것으로 예상됩니다.
카마다는 2025년 하반기에 미국 FDA와 유럽 의약품청에 승인 신청서를 제출할 계획이며, 제출 후 9-12개월 이내에 승인 결정을 받을 것으로 예상하고 있습니다.
Kamada (NASDAQ: KMDA) a annoncé l'ouverture d'un nouveau centre de collecte de plasma à San Antonio, Texas, marquant sa troisième installation de ce type. Le centre de 11 100 pieds carrés, géré par Kamada Plasma, disposera de près de 50 lits pour donneurs avec une capacité de collecte annuelle estimée à 50 000 litres.
La structure collectera à la fois du plasma normal et du plasma spécial (Anti-Rage et Anti-D), soutenant la demande croissante de l'entreprise pour du plasma hyper-immun et visant à réduire les coûts des matières premières. À pleine capacité, le centre devrait générer 8 à 10 millions de dollars de revenus annuels grâce aux ventes de plasma normal à des tiers.
Kamada prévoit de soumettre des demandes d'approbation à la FDA américaine et à l'
Kamada (NASDAQ: KMDA) hat die Eröffnung eines neuen Plasmasammelzentrums in San Antonio, Texas bekannt gegeben, was die dritte solche Einrichtung markiert. Das 11.100 Quadratfuß große Zentrum, das von Kamada Plasma betrieben wird, wird fast 50 Spenderbetten umfassen und hat eine geschätzte jährliche Sammlungskapazität von 50.000 Litern.
Die Einrichtung wird sowohl normales Plasma als auch Spezialplasma (Anti-Hundebiss und Anti-D) sammeln, um der steigenden Nachfrage des Unternehmens nach hyperimmunem Plasma gerecht zu werden und die Rohstoffkosten zu senken. Bei voller Kapazität wird das Zentrum voraussichtlich 8-10 Millionen Dollar jährlichen Umsatz aus dem Verkauf von normalem Plasma an Dritte generieren.
Kamada plant, in der zweiten Hälfte des Jahres 2025 Genehmigungsanträge bei der US FDA und der Europäischen Arzneimittel-Agentur einzureichen, wobei mit Genehmigungsentscheidungen innerhalb von 9-12 Monaten nach Einreichung gerechnet wird.
- New facility expected to generate $8-10M annual revenue from plasma sales
- 50,000 liters annual collection capacity expansion
- Anticipated reduction in raw material costs
- Expansion of specialty plasma collection capability
- 9-12 month regulatory approval timeline before full operations can begin
- Significant wait time until revenue generation (pending regulatory approvals)
Insights
Kamada's expansion into a third plasma collection center represents a significant vertical integration move with clear financial benefits. The projected
Beyond direct revenue generation, this facility offers two powerful financial advantages: cost reduction for their own plasma-derived products through internal sourcing of specialty plasma (Anti-Rabies and Anti-D), and diversification of revenue streams through third-party plasma sales. The 50,000-liter annual collection capacity provides considerable operational flexibility to balance between internal manufacturing needs and market sales based on prevailing conditions.
While the regulatory approval timeline (submissions in H2 2025 with 9-12 month review periods) indicates that full financial impact won't materialize until 2026-2027, the strategic benefits begin immediately through enhanced supply chain control. This reduces dependency on external plasma suppliers in a market where specialty plasma can face supply constraints and price volatility.
The investment demonstrates disciplined capital allocation, as building collection infrastructure typically yields better long-term returns than purchasing raw materials at market prices, especially for specialty plasma with suppliers. The San Antonio location also provides geographic diversification from existing Texas operations while leveraging regional expertise.
Kamada's new plasma collection center addresses a critical supply chain vulnerability in the specialty biologics sector. By expanding their collection capacity for specialty plasma like Anti-Rabies and Anti-D, they're securing a consistent supply of these difficult-to-source raw materials that are essential to their proprietary manufacturing processes.
The 50,000-liter annual collection capacity is substantial, allowing them to optimize for either specialty plasma collection or normal source plasma based on market conditions and internal production requirements. This flexibility creates significant operational advantages as specialty plasma markets often experience supply constraints due to collection networks.
Vertically integrating backward in the supply chain specifically for specialty plasma provides Kamada with a competitive moat in their hyper-immune products. When competitors might face raw material shortages or price increases, Kamada will maintain stable production costs and consistent product availability – critical factors for hospitals and healthcare systems that rely on these specialized treatments.
The facility's dual-purpose design (collecting both specialty and normal source plasma) is particularly astute, as it optimizes collection economics regardless of donation patterns or product demand fluctuations. While regulatory approvals will take time, the infrastructure investment positions Kamada to capture increasing market share in the specialty plasma-derived therapeutics space where supply chain resilience is a key competitive differentiator.
- New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters
- Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D
- Specialty Plasma Collected will Support the Company’s Increasing Demand for Hyper-Immune Plasma, and is Expected to Lower Raw Material Costs
- Expected Annual Revenue Contribution from Sales of Normal Source Plasma is Estimated at
$8 Million to$10 Million at Full Capacity - New Center Opening Furthers Kamada’s Growth Strategy
REHOVOT, Israel and HOBOKEN, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced the expansion of its plasma collection operations with the opening of a third plasma collection center. The new 11,100 square foot center in San Antonio, TX, is operated by Kamada’s wholly owned subsidiary, Kamada Plasma, and is planned to support close to 50 donor beds with an estimated total collection capacity of approximately 50,000 liters annually.
“We are extremely pleased to announce the opening of our new state-of-the-art plasma collection center in San Antonio,” said Amir London, Chief Executive Officer of Kamada. “The opening of this center will expand the collection capacity of specialty plasma, such as Anti-Rabies and Anti-D, for our internal use beyond our existing sites in Beaumont and Houston, TX. The collected specialty plasma will support our increasing demand for hyper-immune plasma and is expected to lower our raw material costs. The new center will also collect normal source plasma to be sold to third parties. We are especially grateful for the skilled and experienced team of plasma collection experts we have appointed to lead the establishment and operations of our new center.”
The new center is expected to contribute annual revenues of
Kamada intends to submit approval applications for the new site to the U.S. FDA and the European Medicines Agency during the second half of 2025, and the Company currently anticipates approval decisions from both agencies within 9-12 months of the submissions.
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, including statements regarding: 1) new plasma collection center in San Antonio is planned to support close to 50 donor beds and has planned annual collection capacity of approximately 50,000 liters, 2) center will collect normal source plasma and specialty plasma, such as Anti-Rabies and Anti-D, 3) expectation that the collected specialty plasma will support our increasing demand for hyper-immune plasma and potentially lower our raw material costs, 4) expected annual revenues contribution from sales of normal source plasma collected in the new site is estimated at
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
What is the expected annual revenue from Kamada's new San Antonio plasma center?
What types of plasma will KMDA collect at its new San Antonio facility?
What is the collection capacity of KMDA's new plasma center?
When does KMDA expect regulatory approvals for its new plasma center?
